Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
COMPANY
ACF Equity Research
Accuracy | Clarity | Foresight
Follow
Location:
United Kingdom
53
Insights
22.6k
Views
3
Followers
Equities
Follow
Regions
Sectors
Verticals
More Filters
Refresh
Top Picks Only
Recent
bullish
•
BrainStorm Cell Therapeutics I
•
12 Nov 2024 22:00
•
Issuer-paid
BrainStorm Cell Therapeutics (BCLI) Update 11112024
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI) develops NurOwn® stem cell therapy for NDDs – BCLI’s first target is ALS (MND/Lou...
ACF Equity Research
Follow
125 Views
Share
bullish
•
CIEL
•
08 Nov 2024 09:27
•
Issuer-paid
Ciel Limited (CIEL) - Conglomerate Strategy Fixes Textile Challenge
CIEL Limited (SEMDEX: CIEL) is a Mauritius listed diversified industrial company with a very attractive long run growth opportunity.
ACF Equity Research
Follow
107 Views
Share
bullish
•
AsiaFIN Holdings
•
02 Nov 2024 09:50
•
Issuer-paid
AsiaFIN Holdings Corp (ASFH) Pre-Results 3Q24 30102024
AsiaFIN Holdings Corp. (OTCQB : ASFH) - aggressive growth inflection point. ASFH provides IP protected fintech solutions to ASEAN based financial...
ACF Equity Research
Follow
352 Views
Share
bullish
•
BrainStorm Cell Therapeutics I
•
04 Oct 2024 00:00
•
Issuer-paid
BrainStorm Cell Therapeutics (BCLI) Update Note 03102024
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI) develops NurOwn® stem cell therapy for NDDs – BCLI’s first target is ALS (MND/Lou Gehrig’s). We...
ACF Equity Research
Follow
267 Views
Share
bullish
•
BrainStorm Cell Therapeutics I
•
01 Oct 2024 00:00
•
Issuer-paid
BrainStorm Cell Therapeutics (BCLI) Flash Note 30092024
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI) develops NurOwn® stem cell therapy for NDDs – BCLI’s first target is ALS (MND/Lou Gehrig’s). BCLI...
ACF Equity Research
Follow
208 Views
Share
1
2
3
4
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.40.5
x